Compagnie Lombard Odier SCmA Purchases 3,200 Shares of Novo Nordisk A/S (NYSE:NVO)

Compagnie Lombard Odier SCmA increased its position in Novo Nordisk A/S (NYSE:NVO) by 5.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 67,745 shares of the company’s stock after acquiring an additional 3,200 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Novo Nordisk A/S were worth $5,827,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of NVO. International Assets Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd bought a new stake in shares of Novo Nordisk A/S in the third quarter worth $98,765,000. DAVENPORT & Co LLC lifted its position in Novo Nordisk A/S by 75.1% during the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after purchasing an additional 451,641 shares in the last quarter. Wellington Management Group LLP purchased a new position in Novo Nordisk A/S during the third quarter valued at $42,017,000. Finally, World Investment Advisors LLC lifted its position in Novo Nordisk A/S by 2,655.9% during the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after purchasing an additional 270,234 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NVO. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Wednesday. They issued an “equal weight” rating on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $78.78 on Friday. The company has a market capitalization of $353.52 billion, a price-to-earnings ratio of 23.94, a PEG ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The firm’s 50-day moving average is $89.91 and its 200 day moving average is $110.40. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is presently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.